I think back to when I was about to have a major surgery for the first time. It was scary, but I was able to focus during the procedure thanks to the trust I had in my surgeon. I assumed the best for my surgery, and I put my confidence in the tools, the devices, and the suggestions to be for my benefit. I never considered the possibility that there could be a financial reason behind things in the operating room.
Then, I became a researcher in the field of healthcare compliance and corporate law. I gained knowledge about a part of the medical field that the majority of patients do not understand. A breach of trust turns out to be a breach of trust when the trust has consequences.
Healthcare compliance has been buzzing due to the news brought on by the lawsuits against a spinal device manufacturer in Utah. The medical device sector has changed because of the Innovasis lawsuits. There is a need for all people in the healthcare field, compliance, and patients to understand the “who, what, when, where, why, and how” of the matter.
We will analyze the main lawsuits against the company and then analyze the details of the newer DOJ Innovasis settlement. We will also look at what these lawsuits mean for the medical device sector as a whole.
Table of Contents
My Personal Journey into Healthcare Compliance
Before we get into the dense legal minutiae, I’d like to outline my background. Several years ago, I began to explore the intricacies surrounding medical devices and how they flow from the manufacturer’s warehouse to the operating room of a hospital. I envisioned the process to be fairly linear: a hospital purchases a great new invention from a company, and the surgeon then uses it in an operation.
The complexity of this matter extends beyond a single line of text. Winning the surgeon’s preference is a leading objective for companies in this industry. I learned about the Anti-Kickback Statute and the False Claims Act. Both laws exist for the same reason: to ensure a conflict of interest from the corporate side doesn’t compromise the quality of patient care.
It’s a little like professional sports. If a team made a deal with a referee to have certain players called for fouls, and others not called, the entire structure of the game falls apart. In healthcare, game mechanics aren’t points on a scoreboard, but actual people.
In some of the first documents I reviewed in connection with the Innovasis lawsuit, I was looking at a case study on why this type of regulation exists. I was reminded immediately why I spend my time focused on healthcare transparency. The lawsuit walks a fine line between marketing and illegal incentives.
What the DOJ Alleged in this Case
As of May 2024, one of the most significant legal developments in this case is the Innovasis settlement with the Department of Justice (DOJ). The Office of Inspector General of the U.S. Department of Health and Human Services (HHS OIG) recently resolved one of its many financial investigations against the company.
In order to understand this case better, we will first analyze the allegations themselves. From January 1, 2014, to December 31, 2022, Innovasis allegedly conducted certain financial activity to encourage seventeen orthopedic and neurosurgeons to use particular spinal implants in their Medicare-reimbursed surgeries.
Warnings from the Legal Advocates
For fraudulent marketing, payments to physicians are gross violations of the Anti-Kickback Statute, are easy to spot, and are intentional, says the lead attorney from Innovasis. The company offered structured, ‘business legitimate’ payments to physicians to avoid direct violations of the law.
One alleged false payment involves consulting fees. In these unproven arrangements, surgeons acting as consultants supposedly received exorbitant payments, such as over 30% appreciation from exercising consulting stock options for nonexistent work.
Payments for unpatented, undervalued, or unused intellectual property are also deemed false payments. Payments to surgeons to enlist them in a registry or give them stock/performance stock options are also deemed as false payments. Tying the financial success of a surgeon to that of the orthopedic manufacturer is creating a conflict of interest.
Sumptuous Bonuses and Getaways
Payments, of course, are only part of the story. The other part is the case of the DOJ, which has now been brought against the free high-end bonuses allegedly awarded to the surgeon, the surgeon’s staff, and the surgeon’s family members. Free extended luxurious gourmet dinners, ski holidays, and Christmas parties are included.
Let’s say you’re trying to hire a contractor to fix your roof. Working outside the law, the contractor may take your entire family on a ski trip. If the contractor is using government (Medicare) money to pay for the trip, it becomes a legal problem for the contractor. This allegedly had to do with enticing the surgeons to make a decision that would corrupt the goal-oriented law of medicine.
For these eight years, company founder and President Brent Felix and his brother, CFO Garth Felix, were the key executives. The DOJ supposedly considered them responsible for the strategy and decisions related to the agreements that made these wrongful payments possible.
The Whistleblower and the $12 Million Innovasis Settlement
Legal investigations of this magnitude rarely start out of nowhere. They often begin with an insider who sees something wrong and decides to speak up.
In this scenario, the investigation was initiated by a whistleblower named Robert Richardson. Richardson was a former regional sales director for the company. Under the qui tam provisions of the False Claims Act, private citizens can sue on behalf of the government if they know of fraud occurring. If the case is successful, the whistleblower is entitled to a portion of the recovered funds.
On May 29, 2024, the legal battle reached a conclusion when the company and its two senior executives agreed to a $12 million Innovasis settlement. Because he blew the whistle and provided crucial insider information, Richardson is set to receive approximately $2.2 million of that settlement payout.
This massive financial penalty serves to resolve the allegations without the company necessarily admitting full legal fault, which is common in False Claims Act resolutions. However, the DOJ Innovasis settlement sends a loud and clear message to the rest of the industry about the consequences of sidestepping compliance laws.
The $50 Million RSB Spine Patent Infringement Lawsuit
While the kickback settlement grabbed most of the headlines, the company is also fighting a completely separate, massive legal battle on another front.
In April 2024, RSB Spine LLC filed a lawsuit against the company in the U.S. District Court for the District of Utah. This case is completely unrelated to kickbacks or Medicare fraud. Instead, it centers on intellectual property and patent infringement.
RSB Spine claims that the company’s Ax® Stand-Alone ALIF System, a device used in spinal surgeries, directly infringes on RSB Spine’s patent (U.S. Patent No. 9,713,537). This specific patent covers a bone-plate stabilization system.
According to the claims in this Innovasis lawsuit, RSB Spine did not just spring this lawsuit on them unexpectedly. RSB alleges that they repeatedly notified the manufacturer of the patent infringement, starting way back in 2018. Despite these repeated warnings, the defendant allegedly refused to enter into any meaningful licensing discussions.
Because of this alleged willful ignorance, the financial stakes in this civil lawsuit are incredibly high. RSB Spine is currently seeking a jury trial, and they are pursuing damages that could reach up to $50 million. If RSB Spine wins, this second legal blow could be financially devastating for the spinal device manufacturer.
Important Lessons Learned from the Innovasis Settlement
Whenever a major settlement occurs in the healthcare space, smart companies pay attention. The DOJ Innovasis settlement serves as a critical reminder for all medical device companies about the absolute necessity of an effective compliance program.
From my time studying corporate compliance, I can tell you that fixing a broken system is always more expensive than building a clean one from the start. Here are the core lessons we can pull from this situation.
1. Strictly Ensure Fair Market Value (FMV)
If you are going to pay a healthcare provider for a service, that payment must strictly reflect fair market value (FMV). If a doctor gives a one-hour lecture, you pay them the industry standard for one hour of their time.
These payments must be thoroughly documented to confirm that the services were actually provided. Overcompensating a surgeon, or paying them for consulting services they never actually performed, creates an immediate red flag for government regulators.
2. Avoid Luxury and Lavish Perks completely
The days of flying doctors out to ski resorts to win their business are over. High-end perks, extravagant parties, and luxury vacations should be strictly avoided by medical sales teams.
Under the Anti-Kickback Statute, these benefits are easily perceived as illegal inducements. Companies must ensure that any hospitality or gifts they offer are highly modest, heavily regulated, and strictly aligned with current industry standards.
3. Conduct Proper Valuation of Intellectual Property
Medical companies frequently buy intellectual property (IP) from brilliant surgeons who invent new tools. However, when acquiring or compensating healthcare providers for intellectual property, it is absolutely crucial to conduct a proper, independent valuation before the purchase.
Furthermore, the company needs to ensure that the purchased IP is actually used effectively in meaningful product development. Buying a doctor’s patent for an inflated price and then letting it gather dust on a shelf looks incredibly suspicious to investigators. It looks exactly like a disguised kickback.
4. Build a Bulletproof Compliance Program
The overarching lesson here is the importance of regular compliance audits and routine monitoring. Continuous evaluation of compliance programs is essential.
Companies must provide comprehensive, mandatory training for all employees, especially executives and sales directors. If your leadership team is not leading by example, the culture of compliance will fail. A strong auditing system can help identify and address potential compliance issues internally before they escalate into a multi-million dollar federal lawsuit.
Broader Implications for the Medical Device Industry
What does the DOJ Innovasis settlement mean for other players in the space? Legal experts and law publications have been analyzing the fallout heavily.
For one, it highlights a ramping up of Anti-Kickback Statute enforcement by the Department of Justice. The government is actively looking for disguised payments and improper relationships between manufacturers and surgeons.
Additionally, the case emphasizes the incredibly delicate balance companies face when they discover internal wrongdoing. Do you self-disclose a violation to the government, or do you wait and hope you do not get caught?
Legal experts point out that this settlement demonstrates how navigating a self-disclosure requires striking the perfect balance between cooperating with the government and advocating for the client. Finding a problem internally and reporting it yourself often leads to more leniency than waiting for a whistleblower like Robert Richardson to take the information straight to the feds.
Frequently Asked Questions
Q. What is the Innovasis lawsuit about?
Innovasis is actually facing two major legal battles. The first involves a $12 million settlement with the Department of Justice (DOJ) to resolve allegations of paying illegal kickbacks to medical professionals. The second is a completely separate, ongoing $50 million civil lawsuit filed by RSB Spine LLC over alleged patent infringement related to spinal implant technology.
Q. Why did Innovasis agree to the $12 million DOJ settlement?
The company agreed to the settlement to resolve claims that it violated the False Claims Act. Between 2014 and 2022, Innovasis allegedly gave improper financial incentives to 17 orthopedic surgeons and neurosurgeons. These incentives included inflated consulting fees, payments for unused intellectual property, and luxury perks like ski trips and lavish dinners, all designed to encourage the doctors to use Innovasis spinal implants in Medicare-covered surgeries.
Q. Who started the kickback investigation against the company?
The federal investigation began because of a whistleblower named Robert Richardson, who previously worked as a regional sales director for Innovasis. Under the False Claims Act, private citizens can report fraud on behalf of the government. Because he provided this crucial inside information, Richardson will receive approximately $2.2 million of the final settlement.
Q. What are the details of the $50 million patent infringement lawsuit?
In April 2024, RSB Spine LLC filed a lawsuit claiming that Innovasis’s Ax® Stand-Alone ALIF System directly copied their patented bone-plate stabilization technology. RSB Spine claims they repeatedly warned Innovasis about the infringement starting back in 2018, but the company refused to discuss licensing. As a result, RSB Spine is now seeking a jury trial and up to $50 million in financial damages.
Conclusion
The dual legal battles facing this spinal device manufacturer offer a masterclass in the complexities of medical compliance and intellectual property law. From the $12 million DOJ Innovasis settlement regarding kickbacks and luxury perks to the looming $50 million patent infringement lawsuit from RSB Spine, the company has a difficult road ahead.
For those of us observing from the outside, the Innovasis lawsuit is a stark reminder that ethics and compliance are not just corporate buzzwords. They are the foundation of patient trust and legal survival.
If you work in the medical device field, now is the time to review your internal compliance protocols. Ensure your fair market value calculations are accurate, audit your intellectual property purchases, and cancel any lavish ski trips you might have planned for your clients.
Trust in healthcare is a fragile thing. It is up to every manufacturer, executive, and sales representative to protect that trust through unwavering legal compliance.
